Literature DB >> 15983392

Improved survival of follicular lymphoma patients in the United States.

Wade T Swenson1, James E Wooldridge, Charles F Lynch, Valerie L Forman-Hoffman, Elizabeth Chrischilles, Brian K Link.   

Abstract

PURPOSE: Despite several new treatment options, single- and multi-institution analyses have not clarified whether survival patterns in follicular lymphoma (FL) patients have changed in recent decades. We undertook a study using a large population-based registry to analyze survival patterns among patients with FL. PATIENTS AND METHODS: Surveillance, Epidemiology, and End Results morphology codes were used to identify 14,564 patients diagnosed with FL between 1978 and 1999. Observed median survival times, Kaplan-Meier survival curves, proportional death hazard ratios, and relative survival rates were calculated. Joinpoint regression analysis was used to identify trends in annual adjusted death hazard ratios.
RESULTS: An improvement in survival of all patients with FL was observed between each of three diagnosis eras (1978 to 1985, 1986 to 1992, and 1993 to 1999) by log-rank tests. Among patients with stage-specific data, the median survival time improved from 84 months (95% CI, 81 to 88 months) in the 1983 to 1989 era to 93 months (95% CI, 89 to 97 months) in the 1993 to 1999 era. Similar findings were identified across sex and age groups and for subsets including advanced-stage, large-cell FL and the combined subset of small cleaved- and mixed-cell FL. The inter-era survival advantage observed in white patients was not observed for black patients. The relative risk of death decreased by 1.8% per year over the 1983 to 1999 observation period.
CONCLUSION: The survival of patients with FL in the United States has improved over the last 25 years. The survival improvement may be a result of the sequential application of effective therapies and improved supportive care.

Entities:  

Mesh:

Year:  2005        PMID: 15983392     DOI: 10.1200/JCO.2005.04.503

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  69 in total

Review 1.  Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?

Authors:  Brian K Link
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

2.  Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.

Authors:  Efrat Dotan; Charu Aggarwal; Mitchell R Smith
Journal:  P T       Date:  2010-03

3.  Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.

Authors:  Nadia Howlader; Lindsay M Morton; Eric J Feuer; Caroline Besson; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-15       Impact factor: 4.254

Review 4.  Investigational strategies in autologous stem cell transplantation for follicular lymphoma.

Authors:  Oliver Weigert; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann; Christian Buske
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 5.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

6.  Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.

Authors:  Daphne de Jong; Ad Koster; Anton Hagenbeek; John Raemaekers; Dennis Veldhuizen; Sabien Heisterkamp; Jan Paul de Boer; Martine van Glabbeke
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

7.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Authors:  Daryl Tan; Sandra J Horning; Richard T Hoppe; Ronald Levy; Saul A Rosenberg; Bronislava M Sigal; Roger A Warnke; Yasodha Natkunam; Summer S Han; Alan Yuen; Sylvia K Plevritis; Ranjana H Advani
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

Review 8.  Unmet needs in the first-line treatment of follicular lymphoma.

Authors:  C Casulo; L Nastoupil; N H Fowler; J W Friedberg; C R Flowers
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

9.  Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy.

Authors:  Daphne Y Xiao; Suhong Luo; Katiuscia O'Brian; Weijian Liu; Kenneth R Carson
Journal:  Leuk Lymphoma       Date:  2016-09-26

10.  Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.

Authors:  Jonathan W Friedberg; Jennifer L Kelly; Donna Neuberg; Derick R Peterson; Jeffery L Kutok; Rabih Salloum; Thomas Brenn; David C Fisher; Elizabeth Ronan; Virginia Dalton; Lynn Rich; Diana Marquis; Paul Sims; Paul G Rothberg; Jane Liesveld; Richard I Fisher; Robert Coffman; Tim Mosmann; Arnold S Freedman
Journal:  Br J Haematol       Date:  2009-06-10       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.